Transcatheter Market Size

Global Transcatheter Market Overview

Transcatheter Market Size was valued at USD 1.9 Billion in 2022. The Transcatheter market industry is projected to grow from USD 2.26 Billion in 2023 to USD 9.23 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 19.20% during the forecast period (2023 - 2032). Increased demand for TAVI procedures and growing geriatric populations are the key market drivers expediting market’s expansion. 

Source Secondary Research, Primary Research, MRFR Database and Analyst Review

Transcatheter Market Trends

• Rising spread of aortic valve stenosis is driving the market growth

Market CAGR for transcatheter is being driven by the rising population of elderly people and growing demand for minimal-invasive processes. Transcatheter aortic valve replacement is a minimally invasive technique that is in high demand due to the increased prevalence of aortic valve stenosis (AS), the growing percentage of elderly population, and the rising need for minimally invasive procedures in general. In the United States, 92,000 TAVR valves were implanted in patients in 2021, according to Cardiovascular Business magazine. The pandemic had a prominent impact on the world's economy and healthcare system. Major producers of cardiovascular equipment experienced significant revenue losses since the pandemic reduced the number of medical operations overall and affected the supply chain for medical devices.

For instance, Boston Scientific's quarterly sales showed a 12% loss in the cardiovascular device market in 2020, while Medtronic's 2020 quarterly financial reports showed a decrease of 33% in its cardiac and vascular portfolio. As a result, the fall in segmental income for important participants points to a serious setback that hurt the sector. Additionally, adults with congenital heart disease were possibly at high risk for mortality and other problems during the pandemic, according to an article titled "COVID-19 in Adults with Congenital Heart Disease" that was published in the Journal of the American College of Cardiology in April 2021.

Additionally, industry innovation keeps improving prospects. For instance, in September 2021, the U.S. FDA approved Abbott Laboratories, Inc.'s Epic Plus, and Epic Plus Supra Stented Tissue Valves to improve the range of treatment options for patients with AS illness. Due to technological advancements in TAVR operations, the market is growing. Additionally, important manufacturers take on several strategic projects that support the development of the sector.

The elderly (65 years of age or older) are more prone to AS. For instance, according to the study Epidemiology of AS and aortic incompetence (AI), AS/AI prevalence was comparable over the world in February 2020. Between rich and developing nations, there are major differences in the epidemiology of AS. In addition, the prevalence of AS rises sharply with age, reaching 9.8% in people 80 to 89 years old, 3.9% in people 70 to 79 years old, 1.3% in people 60 to 69 years old, and 0.2% in people 50 to 59 years old. As a result, these studies show that patients with AS use transcatheter heart valves, and the demand for TAVR is anticipated to increase throughout the projected period. Thus, driving the Transcatheter market revenue.

Transcatheter Market Segment Insights

The Transcatheter market segmentation, based on type includes the transapical approach, transaortic approach, and transfemoral approach. The market was controlled by the transfemoral approach category. The transfemoral approach has grown in popularity among patients because of its ease of use, ability to allow for early mobility, availability of awake procedures, quick turnaround times, and less need for incisions.

Transcatheter End-User Insights

The Transcatheter market segmentation, based on end-user, includes ambulatory surgical centers, cardiac catheterization laboratories, and hospitals. Due to rising AS and more TAVR treatments, hospitals have the greatest market share. The American College of Cardiology Foundation reports that in U.S. hospitals in 2019, there were 72,991 TAVR procedures carried out. Additionally, segment expansion is being fueled by technological developments in TAVR devices and systems, bettering healthcare infrastructure, and favorable reimbursement circumstances in both developed and developing nations.

Figure 1 Transcatheter Market, by End-User, 2022 & 2032 (USD Billion)

Source Secondary Research, Primary Research, MRFR Database, and Analyst Review

Transcatheter Regional Insights

By region, the study provides market insights into North America, Europe, Asia-Pacific, and the Rest of the World. The North American Transcatheter market area will dominate this market. Due to its well-established healthcare system and the rising prevalence of conditions like regurgitation and AS. Growth in the region is projected to be fueled by the increased prevalence of AS illnesses and aortic regurgitation in the populace over the anticipated period.

Further, the major countries studied in the market report are The US, Canada, German, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Figure 2 TRANSCATHETER MARKET SHARE BY REGION 2022 (USD Billion)

Source Secondary Research, Primary Research, MRFR Database, and Analyst Review

Europe’s Transcatheter market accounts for the second-largest market share. The market is influenced by several variables, including an increase in TAVR treatments, economic growth, regulatory repercussions, and new product introductions in the EU. Further, the German Transcatheter market held the largest market share, and the UK Transcatheter market was the fastest-growing market in the European region

The Asia-Pacific Transcatheter Market is anticipated to expand at the quickest CAGR. Due to rising aortic stenosis disease prevalence, expanding healthcare infrastructure, and increased knowledge of transcatheter aortic valve implantation. As a result of its huge population and several cardiovascular and lifestyle disorders, Asia-Pacific presents lucrative potential for participants in the transcatheter aortic valve implantation market. Moreover, China’s Transcatheter market held the largest market share, and the Indian Transcatheter market was the fastest-growing market in the Asia-Pacific region.

Transcatheter Key Market Players & Competitive Insights

Leading market players are investing largely across research & development activities to expand their product lines, which will help the Transcatheter market, grow substantially. Market leaders are also undertaking a variety of strategies to extend their presence, with vital market developments including new product developments, contracts & agreements, mergers & acquisitions, investments, and collaboration with other similar organizations. To grow and sustain in a more competitive and rising market climate, the Transcatheter industry must offer cost-effective items.

Manufacturing locally to reduce operational expenses is one of the key business tactics used by manufacturers in the Transcatheter industry to benefit clients and increase the market sector. In recent years, the Transcatheter industry has offered some of the most significant advantages to medicine. Major players in the Transcatheter market, including Edwards Lifesciences Corporation, Meril Life Sciences Pvt. Ltd., Braile Biomedica, Venus Medtech, Boston Scientific Corporation, JenaValve Technology Inc., Abbot Laboratories, Medtronic PLc, Bracco Diagnostics Inc., Cook Medical Inc., and others, are trying to extend market demand by investing in research and development operations.

The development, production, and marketing of devices for structural heart disease, critical care, and postoperative monitoring are the main business activities of Edwards Lifesciences Corp (Edwards Lifesciences). The company produces pressure monitoring equipment, transcatheter cardiac valves, hemodynamic monitoring equipment, surgical valve replacement equipment, and related tools and accessories. Its products are used in several therapeutic procedures, including transcatheter aortic valve replacement (TAVR), blood preservation, infection control, accelerated surgical recovery, and the treatment of clotting, hypotension, and sepsis. Among other places, the company markets its goods through a network of independent distributors in North America, Europe, and Asia-Pacific. In November 2022, The EVOQUE transcatheter tricuspid valve replacement device from Edwards Lifesciences Corporation produced positive results after one year for patients treated in the single-arm, prospective, worldwide, multi-center TRISCEND research, which looked at safety, effectiveness, and quality of life. The information was provided at PCR London Valves 2022's late-breaking trials session.

A wide variety of healthcare goods are discovered, developed, produced, and sold by Abbott Laboratories (Abbott), including branded generic medications, diagnostic tools and procedures, and infant, child, & nutritional supplements for adults. The company also provides various medical devices, like those for neuromodulation, electrophysiology, rhythm control, vascular and structural cardiac devices, and heart failure. The business also sells dietary supplements, minerals, and nutrition goods. It runs manufacturing sites all around the world and has research and development centers in the US, China, Colombia, India, Singapore, Spain, and the UK. The corporation sells its goods across Africa, the Middle East, Latin America, North America, and the Asia-Pacific region. In January 2023, To treat patients with severe aortic stenosis who are at peak or extremely high risk for open-heart surgery, Navitor, Abbott's most recent generation transcatheter aortic valve implantation (TAVI) technology, has been given FDA approval. The company's extensive transcatheter structural heart portfolio, which includes the Navitor TAVI device, offers physicians and patients less invasive treatment alternatives for some of the most prevalent and critical heart ailments.

Key Companies in the Transcatheter market include

• Edwards Lifesciences Corporation,


• Meril Life Sciences Pvt. Ltd.,


• Braile Biomedica,


• Venus


• Medtech,


• Boston Scientific Corporation,


• JenaValve Technology Inc.,


• Abbot Laboratories,


• Medtronic PLc,


• Bracco Diagnostics Inc.,


• Cook Medical Inc.

Transcatheter Industry Developments

June 2023 A strategic agreement between ignite, Inc. and JenaValve Technology, Inc. has been announced to shed light on the treatment model and associated results for patients with aortic regurgitation (AR). The partnership uses the market-leading database of lignite to measure prevalence and treatment trends. It has been conservatively estimated that approximately 500,000 people may have been diagnosed with moderate or severe AR in the United States.

February 2023 To treat congenital heart disease patients with a native or surgically repaired right ventricular outflow tract (RVOT), Medtronic has announced the reintroduction of the Harmony Transcatheter Pulmonary Valve (TPV) System.

Transcatheter Market Segmentation

Transcatheter Type Outlook (USD Billion, 2018-2032)

• Transapical approach


• Transaortic approach


• Transfemoral approach

Transcatheter End-user Outlook (USD Billion, 2018-2032)

• Ambulatory surgical center


• Cardiac catheterization laboratory


• Hospital

Transcatheter Regional Outlook

• 
  North America
  
  
  
  • US
  
  
  • Canada
  
  
  
  


• 
  Europe
  
  
  
  • Germany
  
  
  • France
  
  
  • UK
  
  
  • Italy
  
  
  • Spain
  
  
  • Rest of Europe
  
  
  
  


• 
  Asia-Pacific
  
  
  
  • China
  
  
  • Japan
  
  
  • India
  
  
  • Australia
  
  
  • South Korea
  
  
  • Australia
  
  
  • Rest of Asia-Pacific
  
  
  
  


• 
  Rest of the World
  
  
  
  • Middle East
  
  
  • Africa
  
  
  • Latin America